WallStSmart

Merck & Company Inc (MRK)vsTenon Medical Inc (TNON)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1430572% more annual revenue ($65.77B vs $4.60M). MRK leads profitability with a 13.6% profit margin vs -270.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

TNON

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 4.3
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for TNON.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TNON1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
89.9%10/10

Revenue surging 89.9% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TNON4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.10M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-220.3%2/10

ROE of -220.3% — below average capital efficiency

Free Cash FlowQuality
$-3.02M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TNON

The strongest argument for TNON centers on Revenue Growth. Revenue growth of 89.9% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TNON

The primary concerns for TNON are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 2.57 is elevated, increasing financial risk.

Key Dynamics to Monitor

MRK profiles as a value stock while TNON is a hypergrowth play — different risk/reward profiles.

TNON carries more volatility with a beta of 1.28 — expect wider price swings.

TNON is growing revenue faster at 89.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Tenon Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tenon Medical, Inc., a medical device company, develops surgical implant systems to optimize sacroiliac joint fixation/fusion surgery and outcomes. The company is headquartered in Los Gatos, California.

Want to dig deeper into these stocks?